Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.39 |
| ▸ | FEN1 | P39748 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10247741 | 0.93 | CYP2C9 (0.51) | PIK3CACYP2C9CYP3A4BRAFCYP2C19 | |
| SCHEMBL10245959 | 0.88 | BRAF (0.57) | PIK3CACYP2C9CYP3A4BRAFCYP2C19 | |
| SCHEMBL298655 | 0.85 | CYP2C9 (0.68) | PIK3CACYP2C9CYP3A4BRAFCYP2C19 | |
| SCHEMBL288134 | 0.84 | PIK3CA (0.49) | PIK3CACYP2C9CYP3A4BRAFCYP2C19 | |
| SCHEMBL10246105 | 0.82 | CYP2C9 (0.61) | CYP2C9CYP3A4BRAFCYP2C19CYP2D6 | |
| SCHEMBL4570651 | 0.81 | CYP2C9 (0.60) | CYP2C9CYP3A4BRAFCYP2C19CYP2D6 | |
| SCHEMBL10246115 | 0.81 | CYP2C9 (0.53) | CYP2C9CYP3A4BRAFCYP2C19CYP2D6 | |
| SCHEMBL10246230 | 0.81 | CYP2C9 (0.55) | CYP2C9CYP3A4BRAFCYP2C19CYP2D6 | |
| SCHEMBL4570653 | 0.81 | CYP2C9 (0.72) | PIK3CACYP2C9CYP3A4BRAFCYP2C19 | |
| SCHEMBL15667561 | 0.81 | CYP3A4 (0.55) | PIK3CACYP2C9CYP3A4BRAFCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | PIK3CA 277/4885CYP2C9 2176/4885CYP3A4 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.